Figures
The Kaplan-Meier curves for Fig. 4A and Fig. 4B are incorrectly switched. The curve that appears as Fig. 4A should be Fig. 4B, and the curve that appears as Fig. 4B should be Fig. 4A. Please see the corrected Fig. 4 here.
Overall survival in Arm A among patients with a ≥2.0-fold (blue line) or <2.0-fold (red line) change from baseline in PLGF is shown in (A). Overall survival in Arm A among patients with a ≥2.0-fold change from baseline in PLGF (blue line) compared with placebo (red line; patients with undetermined PLGF status were excluded) is shown in (B).
Reference
Citation: The PLOS ONE Staff (2015) Correction: Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience. PLoS ONE 10(3): e0121162. https://doi.org/10.1371/journal.pone.0121162
Published: March 26, 2015
Copyright: © 2015 The PLOS ONE Staff. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited